fluorouracil has been researched along with Kidney Diseases in 48 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer." | 9.11 | Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. ( Bajetta, E; Buzzoni, R; Catena, L; Celio, L; Della Torre, S; Gattinoni, L; Longarini, R; Mariani, L; Procopio, G; Ricotta, R; Zilembo, N, 2005) |
| "To evaluate the safety and efficacy of capecitabine in older women with advanced breast cancer." | 5.11 | Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. ( Bajetta, E; Buzzoni, R; Catena, L; Celio, L; Della Torre, S; Gattinoni, L; Longarini, R; Mariani, L; Procopio, G; Ricotta, R; Zilembo, N, 2005) |
| "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function." | 3.67 | Allergic reaction to 5-fluorouracil infusion. ( Sridhar, KS, 1986) |
| "Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5-fluorouracil (5-FU) had renal impairment 6-11 months from the beginning of MMC therapy." | 3.66 | Renal disease after mitomycin C therapy. ( Hanna, WT; Krauss, S; Murphy, WM; Regester, RF, 1981) |
| "Patients with solid tumors were eligible if they were able to fit into one of three organ dysfunction cohorts: I, creatinine >1." | 2.71 | Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. ( Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| " These results raise the possibility that the dose-limiting factor of low-dose FP therapy may account for the total dosage of CDDP." | 2.69 | [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers]. ( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takasaki, M; Tsuji, A, 1999) |
| "courses in 15 patients with cancer of different origins." | 2.68 | Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. ( Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM, 1995) |
| " We also explore different dosing and schedules of capecitabine administration." | 2.46 | Safety of capecitabine: a review. ( Marshall, JL; Mikhail, SE; Sun, JF, 2010) |
| "The dosage of cisplatin is adjusted according to creatinine clearance (Ccr) estimated by the Cockcroft-Gault formula, which is commonly used as a marker for renal function." | 1.51 | [Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer]. ( Ishizawa, A; Ito, A; Miyazaki, M; Nagai, T; Sagara, A; Senzaki, K; Takagi, M; Yamada, K, 2019) |
| " Nephrotoxicity that developed within 14 days following CDDP administration was evaluated in accordance with Common Terminology Criteria for Adverse Events ver." | 1.46 | Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. ( Enokiya, T; Ikemura, K; Ishinaga, H; Iwamoto, T; Katayama, N; Mizuno, T; Muraki, Y; Oda, H; Okamoto, A; Okuda, M; Oshima, K; Takeuchi, K, 2017) |
| "Fifty-eight patients with head and neck cancer who received cisplatin, docetaxel, and 5-fluorouracil (DCF) were retrospectively investigated." | 1.46 | Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. ( Dosaka-Akita, H; Honma, R; Iseki, K; Kasashi, K; Kinoshita, I; Kobayashi, M; Saito, Y; Shimizu, Y; Takeuchi, S; Yamada, T, 2017) |
| "Here, we examined 95 patients with oesophageal cancer who received 5-fluorouracil and cisplatin (FP) to determine whether nephrotoxicity was affected by SLC22A2 808G>T polymorphism." | 1.39 | Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies. ( Hinai, Y; Miura, M; Motoyama, S; Niioka, T, 2013) |
| " Our findings suggest that it is necessary to manage drug dosage for Japanese patients while considering their renal function, and to actively monitor for any side effects." | 1.38 | [Side effect analyses in consideration of renal functions for capecitabine-administered patients]. ( Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T, 2012) |
| "In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
| "The expanding use of cytotoxic drugs in cancer therapy has resulted in a confusing and increasingly frequent array of severe renal complications." | 1.27 | Renal complications of cytotoxic therapy. ( Clarkson, AR; Healy, HG, 1983) |
| " Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion." | 1.27 | Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. ( Dodge, RK; Forastiere, AA; Goren, MP; Horowitz, ME; Kamen, BA; Pratt, CB; Viar, MJ; Wright, RK, 1987) |
| "Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days." | 1.27 | Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (35.42) | 18.7374 |
| 1990's | 7 (14.58) | 18.2507 |
| 2000's | 10 (20.83) | 29.6817 |
| 2010's | 11 (22.92) | 24.3611 |
| 2020's | 3 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, SH | 1 |
| Chavani, O | 1 |
| Burns, K | 1 |
| Porter, D | 1 |
| Findlay, M | 1 |
| Helsby, N | 1 |
| Sugisaki, T | 1 |
| Aoyama, T | 1 |
| Kawakami, K | 1 |
| Yokokawa, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, W | 1 |
| Ogura, M | 1 |
| Ichimura, T | 1 |
| Chin, K | 1 |
| Yamaguchi, K | 1 |
| Hanaoka, S | 1 |
| Hayashi, H | 1 |
| Yamaguchi, M | 1 |
| Takagi, M | 1 |
| Sagara, A | 1 |
| Ishizawa, A | 1 |
| Ito, A | 1 |
| Miyazaki, M | 1 |
| Senzaki, K | 1 |
| Nagai, T | 1 |
| Yamada, K | 1 |
| Shim, HJ | 1 |
| Kim, HJ | 1 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Chung, IJ | 1 |
| Lee, DH | 1 |
| Mi, YT | 1 |
| Lee, JK | 1 |
| Lim, SC | 1 |
| Chung, JW | 1 |
| Cho, SH | 1 |
| Ikemura, K | 1 |
| Oshima, K | 1 |
| Enokiya, T | 1 |
| Okamoto, A | 1 |
| Oda, H | 1 |
| Mizuno, T | 1 |
| Ishinaga, H | 1 |
| Muraki, Y | 1 |
| Iwamoto, T | 1 |
| Takeuchi, K | 1 |
| Katayama, N | 1 |
| Okuda, M | 1 |
| Bano, N | 1 |
| Ikram, R | 1 |
| Liu, XY | 1 |
| Zhang, FR | 1 |
| Shang, JY | 1 |
| Liu, YY | 1 |
| Lv, XF | 1 |
| Yuan, JN | 1 |
| Zhang, TT | 1 |
| Li, K | 1 |
| Lin, XC | 1 |
| Liu, X | 1 |
| Lei, Q | 1 |
| Fu, XD | 1 |
| Zhou, JG | 1 |
| Liang, SJ | 1 |
| Hinai, Y | 1 |
| Motoyama, S | 1 |
| Niioka, T | 1 |
| Miura, M | 1 |
| Trip, AK | 1 |
| Nijkamp, J | 1 |
| van Tinteren, H | 1 |
| Cats, A | 1 |
| Boot, H | 1 |
| Jansen, EP | 1 |
| Verheij, M | 1 |
| Saito, Y | 1 |
| Kobayashi, M | 1 |
| Yamada, T | 1 |
| Kasashi, K | 1 |
| Honma, R | 1 |
| Takeuchi, S | 1 |
| Shimizu, Y | 1 |
| Kinoshita, I | 1 |
| Dosaka-Akita, H | 1 |
| Iseki, K | 1 |
| Soga, N | 1 |
| Yamada, Y | 1 |
| Nishikawa, K | 1 |
| Hasegawa, Y | 1 |
| Kise, H | 1 |
| Arima, K | 1 |
| Sugimura, Y | 1 |
| Kawazoe, H | 2 |
| Sugishita, H | 1 |
| Watanabe, S | 1 |
| Tanaka, A | 1 |
| Morioka, J | 1 |
| Suemaru, K | 1 |
| Watanabe, Y | 1 |
| Kawachi, K | 1 |
| Araki, H | 1 |
| Mikhail, SE | 1 |
| Sun, JF | 1 |
| Marshall, JL | 1 |
| Rasouli, HA | 1 |
| Moghadam, MM | 1 |
| Tabatabaiefar, M | 1 |
| Taslimi, F | 1 |
| Sheybani, KM | 1 |
| Alidoosti, A | 1 |
| Ameri, A | 1 |
| Fadavi, P | 1 |
| Aref, S | 1 |
| Iwai, M | 1 |
| Kimura, M | 1 |
| Yoshimura, T | 1 |
| Yasuda, T | 1 |
| O'Shaughnessy, JA | 1 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Kim, TW | 1 |
| Bahng, H | 1 |
| Chang, HM | 1 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Park, JS | 1 |
| Louvet, C | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 1 |
| Gamelin, E | 1 |
| de Gramont, A | 1 |
| Tebbutt, NC | 1 |
| Norman, AR | 1 |
| Cunningham, D | 1 |
| Allen, M | 1 |
| Chau, I | 1 |
| Oates, J | 1 |
| Hill, M | 1 |
| Fleming, GF | 1 |
| Schilsky, RL | 1 |
| Schumm, LP | 1 |
| Meyerson, A | 1 |
| Hong, AM | 1 |
| Vogelzang, NJ | 1 |
| Ratain, MJ | 1 |
| Bajetta, E | 1 |
| Procopio, G | 1 |
| Celio, L | 1 |
| Gattinoni, L | 1 |
| Della Torre, S | 1 |
| Mariani, L | 1 |
| Catena, L | 1 |
| Ricotta, R | 1 |
| Longarini, R | 1 |
| Zilembo, N | 1 |
| Buzzoni, R | 1 |
| Jensen, SA | 1 |
| Sørensen, JB | 1 |
| Shord, SS | 1 |
| Thompson, DM | 1 |
| Krempl, GA | 1 |
| Hanigan, MH | 1 |
| Lempert, KD | 1 |
| Powis, G | 1 |
| Bukowski, RM | 2 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Bonnet, JD | 1 |
| Chen, TT | 1 |
| Healy, HG | 1 |
| Clarkson, AR | 1 |
| Yamada, F | 1 |
| Kagami, H | 1 |
| Fukutome, A | 1 |
| Mastumine, T | 1 |
| Miura, T | 1 |
| Hanna, WT | 1 |
| Krauss, S | 1 |
| Regester, RF | 1 |
| Murphy, WM | 1 |
| Vexler, AM | 1 |
| Mou, X | 1 |
| Gabizon, AA | 1 |
| Gorodetsky, R | 1 |
| Uchino, J | 1 |
| Une, Y | 1 |
| Sato, Y | 1 |
| Gondo, H | 1 |
| Nakajima, Y | 1 |
| Sato, N | 1 |
| Valik, D | 1 |
| Tsuji, A | 1 |
| Morita, S | 1 |
| Horimi, T | 1 |
| Takasaki, M | 1 |
| Takahashi, I | 1 |
| Shirasaka, T | 1 |
| Park, TK | 1 |
| Kim, SN | 1 |
| Kim, SW | 1 |
| Kim, GE | 1 |
| Suh, CO | 1 |
| Chabner, BA | 1 |
| Myers, CE | 1 |
| Coleman, CN | 1 |
| Johns, DG | 1 |
| Tangen, C | 1 |
| Lee, R | 1 |
| Macdonald, JS | 1 |
| Einstein, AB | 1 |
| Peterson, R | 1 |
| Fleming, TR | 1 |
| Gebbia, V | 1 |
| Valenza, R | 1 |
| Testa, A | 1 |
| Zerillo, G | 1 |
| Restivo, S | 1 |
| Cupido, G | 1 |
| Ingria, F | 1 |
| Spadafora, G | 1 |
| Barbaccia, C | 1 |
| Cannata, G | 1 |
| Metz-Kurschel, U | 1 |
| Kurschel, E | 1 |
| Wagner, K | 1 |
| Aulbert, E | 1 |
| Graben, N | 1 |
| Philipp, T | 1 |
| Goren, MP | 1 |
| Forastiere, AA | 1 |
| Wright, RK | 1 |
| Horowitz, ME | 1 |
| Dodge, RK | 1 |
| Kamen, BA | 1 |
| Viar, MJ | 1 |
| Pratt, CB | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Schutt, AJ | 1 |
| Douglass, HO | 1 |
| Dimery, IW | 1 |
| Legha, SS | 1 |
| Abe, T | 1 |
| Yashige, H | 1 |
| Inazawa, J | 1 |
| Yokota, S | 1 |
| Tsuda, S | 1 |
| Taniwaki, M | 1 |
| Takeda, S | 1 |
| Misawa, S | 1 |
| Takino, T | 1 |
| O'Connell, MJ | 1 |
| Moertel, CG | 2 |
| Kvols, LK | 1 |
| Hahn, RG | 1 |
| Rubin, J | 1 |
| Dy, C | 1 |
| Gil, A | 1 |
| Algarra, SM | 1 |
| Aparicio, LA | 1 |
| Calvo, F | 1 |
| Herranz, P | 1 |
| Sridhar, KS | 1 |
| Adelstein, DJ | 1 |
| Sharan, VM | 1 |
| Earle, AS | 1 |
| Shah, AC | 1 |
| Vlastou, C | 1 |
| Haria, CD | 1 |
| Carter, SG | 1 |
| Damm, C | 1 |
| Hines, JD | 1 |
| Merlano, M | 1 |
| Tatarek, R | 1 |
| Grimaldi, A | 1 |
| Margarino, G | 1 |
| Rosso, R | 1 |
3 reviews available for fluorouracil and Kidney Diseases
| Article | Year |
|---|---|
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Topics: Antineoplastic Agents; Aspartic Acid; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Fluoroura | 1982 |
The clinical pharmacology of antineoplastic agents (first of two parts).
Topics: Animals; Antineoplastic Agents; Asparaginase; Binding Sites; Biological Transport; Chemical and Drug | 1975 |
13 trials available for fluorouracil and Kidney Diseases
| Article | Year |
|---|---|
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dr | 2009 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bilirubin; Creatinine; Dose-Response Relationship, Dru | 2003 |
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast | 2005 |
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Therapy, | 1983 |
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1995 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1993 |
[Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administratio | 1992 |
Folate nephropathy occurring during cytotoxic chemotherapy with high-dose folinic acid and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; Gastrointesti | 1990 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
32 other studies available for fluorouracil and Kidney Diseases
| Article | Year |
|---|---|
Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Drug-Related Side Effec | 2021 |
Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Kidney Diseases; | 2022 |
[Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati | 2019 |
Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplati | 2020 |
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2017 |
Histopathological and biochemical assessment of kidney damage in albino wistar rats treated with cytotoxic platinum compounds in combination with 5-FU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Creatinine; Fluorour | 2017 |
Renal inhibition of miR-181a ameliorates 5-fluorouracil-induced mesangial cell apoptosis and nephrotoxicity.
Topics: Animals; Apoptosis; Base Sequence; Fluorouracil; HCT116 Cells; Humans; Inflammation; Inhibitor of Ap | 2018 |
Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Blood Cell Count; Chemoradioth | 2013 |
IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycyt | 2014 |
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplements; Docetaxel; Fem | 2017 |
[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Creatine; | 2010 |
Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Urea Nitrogen; Capecitabine; Chemoradiother | 2012 |
[Side effect analyses in consideration of renal functions for capecitabine-administered patients].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials | 2002 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Diarrhea; Drug | 2003 |
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Atherosclerosis; Capecitabine; | 2006 |
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Topics: Albuterol; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atenolol; Cispla | 2006 |
Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C.
Topics: Aged; Anemia, Hemolytic; Fluorouracil; Humans; Kidney; Kidney Diseases; Male; Mitomycins; Stomach Ne | 1980 |
Renal complications of cytotoxic therapy.
Topics: Animals; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Cytarabine; Dogs; Fluorou | 1983 |
[Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney].
Topics: Aged; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Diseases; Male; Mitomycin; Mitomycins; | 1983 |
Renal disease after mitomycin C therapy.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Creatinine; F | 1981 |
Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity.
Topics: Acidosis, Lactic; Ammonia; Brain Diseases; Chemical and Drug Induced Liver Injury; Citric Acid Cycle | 1998 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; D | 1992 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
The use of diamox in the sequential methotrexate-5-fluorouracil therapy of advanced gastrointestinal cancer.
Topics: Acetazolamide; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gastrointestinal Neopla | 1988 |
Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Eval | 1986 |
Allergic reaction to 5-fluorouracil infusion.
Topics: Angioedema; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dru | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |